Cara Therapeutics | CARA - Operating Expenses


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview

Cara Therapeutics

Cara Therapeutics reported $33.82M in Operating Expenses for its fiscal quarter ending in March of 2023.


Operating Expenses Change
Acadia Pharmaceuticals ACAD:US USD 172.05M 10.51M
Cara Therapeutics CARA:US USD 33.82M 753K
Chugai Pharma 4519:JP JPY 213.94B 75.08B
Depomed DEPO:US USD 37.82M 1.91M
Endo International ENDP:US USD 511.81M 280.86M
Halozyme Therapeutics HALO:US USD 108.34M 1.35M
Horizon Pharma HZNP:US USD 796.06M 27.97M
J&J JNJ:US USD 25.48B 5.98B
Neurocrine Biosciences NBIX:US USD 534.6M 226M
Pacira PCRX:US USD 180.36M 1.49M
Pfizer PFE:US USD 11.5B 7.63B
RedHill Biopharma RDHL:US USD 22.75M 1.91M
Revance Therapeutics RVNC:US USD 107.36M 86.97M
Supernus Pharmaceuticals SUPN:US USD 148.59M 15.59M
Vanda Pharmaceuticals VNDA:US USD 60.49M 2.64M